PURPOSE: The heterogeneity of diffuse large B-cell lymphoma (DLBCL) has prompted the search for new markers that can accurately separate prognostic risk groups. We previously showed in a multivariate model that LMO2 mRNA was a strong predictor of superior outcome in DLBCL patients. Here, we tested the prognostic impact of LMO2 protein expression in DLBCL patients treated with anthracycline-based chemotherapy with or without rituximab. PATIENTS AND METHODS: DLBCL patients treated with anthracycline-based chemotherapy alone (263 patients) or with the addition of rituximab (80 patients) were studied using immunohistochemistry for LMO2 on tissue microarrays of original biopsies. Staining results were correlated with outcome. RESULTS: In anthracycline-treated patients, LMO2 protein expression was significantly correlated with improved overall survival (OS) and progression-free survival (PFS) in univariate analyses (OS, P = .018; PFS, P = .010) and was a significant predictor independent of the clinical International Prognostic Index (IPI) in multivariate analysis. Similarly, in patients treated with the combination of anthracycline-containing regimens and rituximab, LMO2 protein expression was also significantly correlated with improved OS and PFS (OS, P = .005; PFS, P = .009) and was a significant predictor independent of the IPI in multivariate analysis. CONCLUSION: We conclude that LMO2 protein expression is a prognostic marker in DLBCL patients treated with anthracycline-based regimens alone or in combination with rituximab. After further validation, immunohistologic analysis of LMO2 protein expression may become a practical assay for newly diagnosed DLBCL patients to optimize their clinical management.
PURPOSE: The heterogeneity of diffuse large B-cell lymphoma (DLBCL) has prompted the search for new markers that can accurately separate prognostic risk groups. We previously showed in a multivariate model that LMO2 mRNA was a strong predictor of superior outcome in DLBCL patients. Here, we tested the prognostic impact of LMO2 protein expression in DLBCL patients treated with anthracycline-based chemotherapy with or without rituximab. PATIENTS AND METHODS: DLBCL patients treated with anthracycline-based chemotherapy alone (263 patients) or with the addition of rituximab (80 patients) were studied using immunohistochemistry for LMO2 on tissue microarrays of original biopsies. Staining results were correlated with outcome. RESULTS: In anthracycline-treated patients, LMO2 protein expression was significantly correlated with improved overall survival (OS) and progression-free survival (PFS) in univariate analyses (OS, P = .018; PFS, P = .010) and was a significant predictor independent of the clinical International Prognostic Index (IPI) in multivariate analysis. Similarly, in patients treated with the combination of anthracycline-containing regimens and rituximab, LMO2 protein expression was also significantly correlated with improved OS and PFS (OS, P = .005; PFS, P = .009) and was a significant predictor independent of the IPI in multivariate analysis. CONCLUSION: We conclude that LMO2 protein expression is a prognostic marker in DLBCL patients treated with anthracycline-based regimens alone or in combination with rituximab. After further validation, immunohistologic analysis of LMO2 protein expression may become a practical assay for newly diagnosed DLBCL patients to optimize their clinical management.
Authors: Keni Gu; Dennis D Weisenburger; Kai Fu; Wing C Chan; Timothy C Greiner; Patricia Aoun; Lynette M Smith; Martin Bast; Zhongfen Liu; R Gregory Bociek; Philip J Bierman; James O Armitage; Julie M Vose Journal: Hematol Oncol Date: 2011-10-18 Impact factor: 5.271
Authors: James R Cerhan; Yasodha Natkunam; Lindsay M Morton; Matthew J Maurer; Yan Asmann; Thomas M Habermann; Mohammad A Vasef; Wendy Cozen; Charles F Lynch; Cristine Allmer; Susan L Slager; Izidore S Lossos; Stephen J Chanock; Nathaniel Rothman; Patricia Hartge; Ahmet Dogan; Sophia S Wang Journal: Leuk Lymphoma Date: 2012-01-03
Authors: J-P Jais; C Haioun; T J Molina; D S Rickman; A de Reynies; F Berger; C Gisselbrecht; J Brière; F Reyes; P Gaulard; P Feugier; E Labouyrie; H Tilly; C Bastard; B Coiffier; G Salles; K Leroy Journal: Leukemia Date: 2008-07-10 Impact factor: 11.528
Authors: Lisa M Rimsza; Michael L Leblanc; Joseph M Unger; Thomas P Miller; Thomas M Grogan; Daniel O Persky; Ralph R Martel; Constantine M Sabalos; Bruce Seligmann; Rita M Braziel; Elias Campo; Andreas Rosenwald; Joseph M Connors; Laurie H Sehn; Nathalie Johnson; Randy D Gascoyne Journal: Blood Date: 2008-06-10 Impact factor: 22.113
Authors: Robert F Luo; Shuchun Zhao; Robert Tibshirani; June H Myklebust; Mrinmoy Sanyal; Rosemary Fernandez; Dita Gratzinger; Robert J Marinelli; Zhi Shun Lu; Anna Wong; Ronald Levy; Shoshana Levy; Yasodha Natkunam Journal: Hum Pathol Date: 2009-12-08 Impact factor: 3.466
Authors: Dita Gratzinger; Shuchun Zhao; Robert West; Robert V Rouse; Hannes Vogel; Elena Cubedo Gil; Ronald Levy; Izidore S Lossos; Yasodha Natkunam Journal: Am J Clin Pathol Date: 2009-02 Impact factor: 2.493